KBC Group
ONC

KBC Group’s BeOne Medicines Ltd ONC Stock Holding History

KBC Group’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.47M Sell
5,171
-4,317
-45% -$1.27M ﹤0.01% 703
2026
Q1 		$2.82M Buy
9,488
+502
+6% +$162K 0.01% 595
2025
Q4 		$2.73M Hold
8,986
– – 0.01% 561
2025
Q3 		$3.06M Hold
8,986
– – 0.01% 520
2025
Q2 		$2.17M Buy
8,986
+49
+0.5% +$12K 0.01% 568
2025
Q1 		$2.43M Hold
8,937
– – 0.01% 561
2024
Q4 		$1.65M Hold
8,937
– – ﹤0.01% 720
2024
Q3 		$2.01M Hold
8,937
– – 0.01% 616
2024
Q2 		$1.27M Hold
8,937
– – ﹤0.01% 641
2024
Q1 		$1.4M Hold
8,937
– – ﹤0.01% 632
2023
Q4 		$1.61M Hold
8,937
– – 0.01% 636
2023
Q3 		$1.61M Sell
8,937
-2,412
-21% -$477K 0.01% 620
2023
Q2 		$2.02M Hold
11,349
– – 0.01% 602
2023
Q1 		$2.45M Hold
11,349
– – 0.01% 615
2022
Q4 		$2.5M Sell
11,349
-2,073
-15% -$380K 0.01% 566
2022
Q3 		$1.81M Sell
13,422
-1,101
-8% -$189K 0.01% 563
2022
Q2 		$2.35M Buy
14,523
+331
+2% +$51.7K 0.01% 515
2022
Q1 		$2.68M Buy
14,192
+125
+0.9% +$26.6K 0.01% 525
2021
Q4 		$3.81M Buy
14,067
+8,720
+163% +$2.94M 0.01% 499
2021
Q3 		$1.94M Sell
5,347
-13
-0.2% -$4.25K 0.01% 664
2021
Q2 		$1.84M Sell
5,360
-246
-4% -$81.5K 0.01% 682
2021
Q1 		$1.95M Sell
5,606
-1,148
-17% -$380K 0.01% 650
2020
Q4 		$1.75M Buy
6,754
+2,321
+52% +$639K 0.01% 669
2020
Q3 		$1.27M Buy
4,433
+282
+7% +$66.3K 0.01% 670
2020
Q2 		$782K Sell
4,151
-1,943
-32% -$316K 0.01% 738
2020
Q1 		$750K Buy
6,094
+130
+2% +$20.3K 0.01% 763
2019
Q4 		$989K Buy
5,964
+2,566
+76% +$426K 0.01% 901
2019
Q3 		$416K Hold
3,398
– – ﹤0.01% 1129
2019
Q2 		$421K Hold
3,398
– – ﹤0.01% 1108
2019
Q1 		$449K Buy
3,398
+776
+30% +$105K ﹤0.01% 1109
2018
Q4 		$368K Buy
+2,622
New +$348K ﹤0.01% 1000

Other funds holding ONC

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

KBC Group's ONC Position: Q2 2026 in Review

KBC Group reduced its BeOne Medicines Ltd (ONC) stake by 45% in Q2 2026, selling an estimated $1.27M and leaving 5,171 shares worth $1.47M. The position accounts for ﹤0.01% of the portfolio, ranked #703.

KBC Group first reported a position in ONC in Q4 2018 and has held it in 31 quarters since. The position peaked at $3.81M in Q4 2021. 283 funds tracked by Wall St. Rank hold ONC as of Q2 2026.

  • KBC Group held 5,171 shares of BeOne Medicines Ltd worth $1.47M as of Q2 2026.
  • KBC Group sold 4,317 BeOne Medicines Ltd shares in Q2 2026, an estimated $1.27M.
  • BeOne Medicines Ltd made up ﹤0.01% of KBC Group's portfolio in Q2 2026, its #703 holding.
  • KBC Group first reported a position in BeOne Medicines Ltd in Q4 2018 and has held it in 31 quarters since.
  • KBC Group's BeOne Medicines Ltd position peaked at $3.81M in Q4 2021.
  • 283 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q2 2026.

Based on KBC Group's 13F filing for Q2 2026, filed 5 Aug 2026.